Immortalized cell line of human jugular paraganglioma and its application

Abstract

The invention provides a human jugular paraganglioma immortalized cell strain, the preservation number of which is: CGMCC NO.19664, and the cell strain is classified and named as a human jugular paraganglioma immortalized cell strain. The cell strain of the present invention is the first jugular bulb paraganglioma cell strain derived from human. There is a mutation of the SDHB gene, which can simulate the phenotype of jugular paraganglioma in the background of human SDHB gene mutation. The cell line is immortalized and can be cultured and subcultured in large quantities. The culture requirements are relatively simple, and a large number of experimental cells can be obtained in a short period of time. The overall experimental cycle is short. The genotype background of the obtained cells is consistent, free of impurities and cells, and is more suitable for basic experiments and promotion than primary cells.

Description

technical field [0001] The invention belongs to the technical field of biology and medical treatment, and in particular relates to an immortalized cell line of human jugular paraganglioma and application thereof. Background technique [0002] At present, the research on glomus jugular tumor is mainly limited to clinical research, and the basic research on tumor occurrence and development is greatly limited due to the lack of suitable cell lines. Previous studies have focused on silencing succinate dehydrogenase B (SDHB) using non-paraneuroma-derived cells or using primary tumor cells. These methods have the following disadvantages: (1) non-paraneuroma-derived cells lack specificity, and cannot actually simulate the true phenotype of jugular paraganglioma; (2) primary tumor cells grow slowly, cannot be passaged, and are affected by patients. (3) The extraction and cultivation of primary cells is more complicated, the cell yield is low, the experiment cycle is longer, the gen...

AI Technical Summary

Problems solved by technology

These methods have the following disadvantages: (1) non-paraneuroma-derived cells lack specificity and cannot actually simulate the true phenotype of jugular bulbar paraganglioma; (2) primary tumor cells grow slowly, cannot be passaged, and are affected by patients. (3) The extraction and cultivation of primary cells are more complicated, the cell yield is low, the experiment cycle is longer, the genotype background of the cells is inconsistent, and a large number of non-tumor cells are mixed. cell

Images